31 August 2018
Visiongain’s study predicts expansion in the bioinformatics market Report will continue until 2026, especially in the genomics sector, which will remain dominant. The chemoinformatics and drug discovery sector will have the highest revenue growth rate during this period, as the use of bioinformatics in personalised medicine increases. In 2015, the genomics submarket formed the most lucrative part of that industry, accounting for 48.6% of the overall world market. As the bioinformatics market grows, this segment will continue to dominate.
The report’s author said: “The bioinformatics market has strong potential, with many innovative software platforms that can offer analysis of not only genomic data but proteomic, transcriptomic and chemoinformatic data. With so many sources of data, a company that can offer integrated analysis and interpretation will have a competitive edge. Researchers will also be looking to bioinformatics companies to provide security and flexibility such as cloud-based bioinformatics to facilitate collaborations and enable data access from anywhere. An important restraint on growth of the market will be a shortage of trained expertise; over our forecast period the success of the market will depend on remedying this deficit. The bioinformatics market will continue to expand, bolstered by governmental investment and lower costs of sequencing, as the trend towards personalised medicine ensures that demand stays strong.”
Visiongain’s new investigation shows bioinformatic revenue predictions to 2026 at overall world market, submarket and regional level. First it forecasts the following segments of the bioinformatics market to 2026:
• Genomics • Metabolomics • Proteomics • Transcriptomics • Chemoinformatics and drug discovery • Other applications.
That work also analyses leading national markets for those informatics tools, providing revenue forecasts to 2026 for these countries and regions:
• United States • European Union • Japan • China • India • Rest of the world.
In addition visiongain’s survey examines leading bioinformatic companies. That study discusses mergers and acquisitions, collaborations and developments, also showing a research interview. The report highlights organisations such as these:
• QIAGEN • Illumina • Thermo Fisher Scientific • 3rd Millennium • DNASTAR • DNAnexus • Compugen.
Bioinformatics Market Analysis, Developments and Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research, manufacturing and selling. Each year new and updated studies appear.
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
26 May 2022
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
19 April 2022
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
13 April 2022
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.